ArticlePloS one2018

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Sehhoon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.